A wholly-owned subsidiary of Sinopharm Modern has received the Approval Notice for the Marketing Authorization Application (MAA) of Nalbuphine Hydrochloride Chemical API

Nov 26, 2025

Leave a message

Recently, Sinopharm Group Industry Co., Ltd. (hereinafter referred to as "Sinopharm Industry"), a wholly-owned subsidiary of Shanghai Modern Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), has received the "Approval Notice for the Marketing Authorization Application of Chemical Active Pharmaceutical Ingredient (API)" issued and approved by the National Medical Products Administration (NMPA) of the People's Republic of China, which approves the marketing authorization application for the API Nalbuphine Hydrochloride. The relevant information is hereby announced as follows:

 

I. Basic Information of the Chemical API

 

Name of Chemical API: Nalbuphine Hydrochloride

Registration Number: Y20230000775

Notice Number: 2024YS01375

Registration Standard Number of Chemical API: YBY76782024

Packaging Specifications: 1kg/bag, 2kg/bag

Manufacturer: Langfang Branch of Sinopharm Group Industry Co., Ltd.

Company Address: Chuangye Road, Langfang Economic and Technological Development Zone

Application Item: Marketing authorization application for domestically produced chemical API

Approval Conclusion: In accordance with the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, this product meets the relevant requirements for drug registration and is approved for registration.

 

II. Drug R&D and Market Status

 

Nalbuphine Hydrochloride is a κ-opioid receptor agonist and μ-opioid receptor antagonist, acting as a potent central analgesic. Its related dosage form product, Nalbuphine Hydrochloride Injection, is mainly used as an adjuvant drug for induction of anesthesia during combined anesthesia, and also for relieving moderate to severe pain.

According to the website of the Center for Drug Evaluation (CDE), other domestic enterprises with a registration status of "A" for Nalbuphine Hydrochloride API currently include Yichang Humanwell Pharmaceutical Co., Ltd., Jiangsu Haici Biopharmaceutical Co., Ltd. of Yangzijiang Pharmaceutical Group, etc. Data from the Pharmaceutical Database Builder (PDB) shows that the global consumption of Nalbuphine API in 2023 was 762.49kg.

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!